Get Started in Minutes
How Fulphila Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
What Is Fulphila?
Pegfilgrastim, which is also known by the brand name, Neulasta, is a hematopoietic agent that is used to treat neutropenia. Neulasta was the first medication produced based on the active element pegfilgrastim. Pegfilgrastim is not a hazardous drug, nor is it a form of chemotherapy.
Based on Neulasta, several different biosimilars have been produced, one of which is called Fulphila. Fulphila is similar to Neulasta in its mechanism of action, administration route, strength, and dosage.
Mechanism of Action
Pegfilgrastim is a blood cell colony-stimulating agent (CSA) and has been used successfully by cancer patients to stimulate the growth of white blood cells, more specifically neutrophils. It does this by stimulating the production of neutrophils directly from the bone marrow.
How Is Fulphila Used?
Fulphila has been approved by the Food and Drug Administration (FDA) for the treatment and prevention of (febrile) neutropenia caused by chemotherapy or radiation.
Fulphila is only available as a subcutaneous (under the skin) injection. The injection is available as a single-use prefilled syringe for subcutaneous injection at a dose of 6 mg/0.6 mL.
The injection sites can include upper areas of the buttocks, front of the thighs, lower abdomen area (2 inches away from the navel), or the upper outer arms. Do not inject into areas where the skin is tender, bruised, red, scaly, or hard, and avoid areas with scars or stretch marks. After injection, do not rub the injection site. Do not handle the prefilled syringe if you are allergic to latex, and do not save unused medication in the prefilled syringe for later use. You should not attempt to give yourself a subcutaneous injection until you have received the appropriate training from your healthcare provider.
If you miss a dose, contact your physician immediately to reschedule.
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Fulphila Side Effects
Serious side effects include:
- Injection-site pain
- Bone and muscle aches
- Thrombocytopenia, leukocytosis
- Lung problem called acute respiratory distress syndrome (ARDS)
- Kidney injury
- Capillary leak syndrome (CLS)
- Inflammation of blood vessels
- Rupture of the spleen
Less severe side effects include:
- Dark urine
Unless approved by your physician, pegfilgrastim is generally not recommended for:
- Patients who have an allergy to human granulocyte colony-stimulating factors (CFS) such as filgrastim or pegfilgrastim products. The needle cap on the prefilled syringe contains natural rubber (derived from latex). Do not handle the prefilled syringe if allergic to latex. Allergic reactions can cause a rash over the whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using Fulphila and call your doctor or get emergency help right away.
- Patients with sickle cell disorder. Using Fulphila can lead to a condition called sickle cell crisis, which may be life-threatening and require discontinuation of Fulphila.
- Patients receiving radiation therapy. Fulphila may increase the risk of developing a precancerous condition called myelodysplastic syndrome (MDS) or a type of blood cancer called acute myeloid leukemia (AML).